Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201191
DOI: 10.1016/j.omton.2026.201191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Konstantinos Vazaios und 13 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Prinses Máxima Centrum Foundation.
Abstract (Originalsprache)
Despite the success of CAR (chimeric antigen receptor) T cells in hematological malignancies, their effectiveness against solid or brain tumors, such as pediatric diffuse midline gliomas (DMGs), is limited. CAR T cell success is hampered by factors including immunosuppression from DMGs and their surrounding tumor microenvironment (TME). Oncolytic viruses (OVs) can reverse this immunosuppression, suggesting a potential combination with CAR T cells. Here, we show that infection with Goravir adenovirus and R124 reovirus induced DMG cell lysis (n = 6 cultures), with minimal effect on the viability of B7H3- or GD2-targeted CAR T cells, even at high virus concentrations. In addition, RNA sequencing of infected tumor cells revealed altered gene expression in cell cycle and antiviral response pathways. Furthermore, co-cultures of CAR T cells with OV-infected DMGs enhanced CAR T-specific anti-tumor killing in 14 out of 24 cases. The successful combinations exhibited enhanced cytokine and chemokine release, coupled with an increased cytotoxic phenotype. These findings highlight the benefit of DMG pre-infection with OVs to boost CAR T cell activity and suggest that immune stimulation is a key driver of enhanced combination responses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
- Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
- Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, the Netherlands.
Förderung
- Prinses Máxima Centrum Foundation
Zitieren
APA
Vazaios, K., Tallon-Cobos, A. C., van Oosterhout, L. P. J., Waranecki, P., Cornel, A. M., Dautzenberg, N. M. M., van Hoesel, M., Forbes, C., Nierkens, S., Kemp, V., Hoeben, R. C., van der Lugt, J., Calkoen, F. G., & Hulleman, E. (2026). Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas. Molecular Therapy Oncology, 34(2), 201191. https://doi.org/10.1016/j.omton.2026.201191
Vancouver
Vazaios K, Tallon-Cobos AC, van Oosterhout LPJ, Waranecki P, Cornel AM, Dautzenberg NMM, et al. Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas. Molecular Therapy Oncology. 2026;34(2):201191. doi:10.1016/j.omton.2026.201191
BibTeX
@article{Vazaios2026,
author = {Vazaios, Konstantinos and Tallon-Cobos, Antonio C and van Oosterhout, Louisa P J and Waranecki, Piotr and Cornel, Annelisa M and Dautzenberg, Noël M M and van Hoesel, Marliek and Forbes, Caitlyn and Nierkens, Stefan and Kemp, Vera and Hoeben, Rob C and van der Lugt, Jasper and Calkoen, Friso G and Hulleman, Esther},
title = {Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201191},
doi = {10.1016/j.omton.2026.201191}
}
EUVIMED